![icad measurements icad measurements](https://slidetodoc.com/presentation_image_h/3273bb6805ac0b55c1098221ad9b4ed4/image-6.jpg)
“Our third quarter 2020 total revenue of $7.1 million represented sequential growth of 28 percent as compared to the second quarter and we achieved over 44% sequential growth in AI product revenue in the third quarter, as ProFound AI continues to gain traction in the market. Cash balance of $22.6 million at the end of the third quarter of 2020.Presented updated positive clinical data for Xoft® Brain IORT demonstrating significant improvement in overall survival and local progression-free survival in patients with recurrent GBM treated with Xoft versus patients treated with external beam radiation therapy and systemic therapy.healthcare system, that will expand access to ProFound AI™ for more hospitals and imaging centers across North America Signed distribution agreement with Change Healthcare, a leading independent healthcare technology company focused on insights, innovation and accelerating the transformation of the U.S.
![icad measurements icad measurements](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12966-017-0526-7/MediaObjects/12966_2017_526_Fig1_HTML.gif)
Data published recently in the peer-reviewed journal, Radiology, showed that our technology significantly outperformed existing breast cancer risk models ProFound AI Risk, the first and only commercially available clinical decision support tool providing accurate two-year breast cancer risk estimation personalized for each woman, currently available on an introductory basis for 2D mammography in the U.S.(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and nine months ended September 30, 2020. New Partnership Agreement Enhances Commercial Access to Enterprise and Integrated Delivery Systems New AI Offering Expands Focus from Current Age Based Detection to 2 Year Risk Assessment and Personalized Screening Regimen Net Loss Improved by $1.2 million to $1.8 million in the Third Quarter of 2020 as Compared to $3.0 million in the Third Quarter of 2019 Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively